Cytokines and hepatitis C virus replication

D. Moradpour, Michael FRESE, H. Heim, Otto Haller, Ralf Bartenschlager, H. E. Blum

Research output: A Conference proceeding or a Chapter in BookConference contribution

Abstract

With an estimated 170 million chronically infected individuals, the hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. A protective vaccine does not exist to date and therapeutic options are still limited. At present, inferon-a (IFN-a) in combination with ribavirin is the treatment of choice for chronic hepatitis C. The mechanism of action of IFN-a is only partially understood and may involve both direct antiviral and immunomodulatory effects. Recently, the replicon system has allowed the investigation of the effect of IF-a and other cytokines on HCV RNA replication. In addition, data obtained in other experimental model systems indicate that HCV has evolved strategies to counteract the antiviral effect of IFN-a. Such mechanisms could contribute to the resistance to IFN-a therapy observed in many patients and may represent a general escape strategy of HCV contributing to viral persistence and pathogenesis. In the following, we will briefly review current concepts of the interaction between cytokines, primarily IFN-a, and HCV.
Original languageEnglish
Title of host publicationCytokines in liver injury and repair
Subtitle of host publicationproceedings of Falk Symposium No. 125
EditorsA. M. Gressner, P. C. Heinrich, S. Matern
Place of PublicationThe Netherlands
PublisherKluwer Academic Publishers
Chapter7
Pages105-120
Number of pages16
ISBN (Electronic)9780792387756
ISBN (Print)0792387759
Publication statusPublished - 2002
EventCytokines in liver injury and repair: proceedings of Falk Symposium No. 125 - Hanover, Hanover, Germany
Duration: 30 Sep 20011 Oct 2001

Conference

ConferenceCytokines in liver injury and repair
CountryGermany
CityHanover
Period30/09/011/10/01

Fingerprint

Virus Replication
Hepacivirus
Cytokines
Antiviral Agents
Replicon
Ribavirin
Chronic Hepatitis C
Chronic Hepatitis
Liver Cirrhosis
Hepatocellular Carcinoma
Theoretical Models
Therapeutics
Vaccines
RNA

Cite this

Moradpour, D., FRESE, M., Heim, H., Haller, O., Bartenschlager, R., & Blum, H. E. (2002). Cytokines and hepatitis C virus replication. In A. M. Gressner, P. C. Heinrich, & S. Matern (Eds.), Cytokines in liver injury and repair: proceedings of Falk Symposium No. 125 (pp. 105-120). The Netherlands: Kluwer Academic Publishers.
Moradpour, D. ; FRESE, Michael ; Heim, H. ; Haller, Otto ; Bartenschlager, Ralf ; Blum, H. E. / Cytokines and hepatitis C virus replication. Cytokines in liver injury and repair: proceedings of Falk Symposium No. 125. editor / A. M. Gressner ; P. C. Heinrich ; S. Matern. The Netherlands : Kluwer Academic Publishers, 2002. pp. 105-120
@inproceedings{03fa362f5ecb4020b7dfc98c4aa657aa,
title = "Cytokines and hepatitis C virus replication",
abstract = "With an estimated 170 million chronically infected individuals, the hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. A protective vaccine does not exist to date and therapeutic options are still limited. At present, inferon-a (IFN-a) in combination with ribavirin is the treatment of choice for chronic hepatitis C. The mechanism of action of IFN-a is only partially understood and may involve both direct antiviral and immunomodulatory effects. Recently, the replicon system has allowed the investigation of the effect of IF-a and other cytokines on HCV RNA replication. In addition, data obtained in other experimental model systems indicate that HCV has evolved strategies to counteract the antiviral effect of IFN-a. Such mechanisms could contribute to the resistance to IFN-a therapy observed in many patients and may represent a general escape strategy of HCV contributing to viral persistence and pathogenesis. In the following, we will briefly review current concepts of the interaction between cytokines, primarily IFN-a, and HCV.",
author = "D. Moradpour and Michael FRESE and H. Heim and Otto Haller and Ralf Bartenschlager and Blum, {H. E.}",
year = "2002",
language = "English",
isbn = "0792387759",
pages = "105--120",
editor = "Gressner, {A. M.} and Heinrich, {P. C.} and S. Matern",
booktitle = "Cytokines in liver injury and repair",
publisher = "Kluwer Academic Publishers",
address = "Netherlands",

}

Moradpour, D, FRESE, M, Heim, H, Haller, O, Bartenschlager, R & Blum, HE 2002, Cytokines and hepatitis C virus replication. in AM Gressner, PC Heinrich & S Matern (eds), Cytokines in liver injury and repair: proceedings of Falk Symposium No. 125. Kluwer Academic Publishers, The Netherlands, pp. 105-120, Cytokines in liver injury and repair, Hanover, Germany, 30/09/01.

Cytokines and hepatitis C virus replication. / Moradpour, D.; FRESE, Michael; Heim, H.; Haller, Otto; Bartenschlager, Ralf; Blum, H. E.

Cytokines in liver injury and repair: proceedings of Falk Symposium No. 125. ed. / A. M. Gressner; P. C. Heinrich; S. Matern. The Netherlands : Kluwer Academic Publishers, 2002. p. 105-120.

Research output: A Conference proceeding or a Chapter in BookConference contribution

TY - GEN

T1 - Cytokines and hepatitis C virus replication

AU - Moradpour, D.

AU - FRESE, Michael

AU - Heim, H.

AU - Haller, Otto

AU - Bartenschlager, Ralf

AU - Blum, H. E.

PY - 2002

Y1 - 2002

N2 - With an estimated 170 million chronically infected individuals, the hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. A protective vaccine does not exist to date and therapeutic options are still limited. At present, inferon-a (IFN-a) in combination with ribavirin is the treatment of choice for chronic hepatitis C. The mechanism of action of IFN-a is only partially understood and may involve both direct antiviral and immunomodulatory effects. Recently, the replicon system has allowed the investigation of the effect of IF-a and other cytokines on HCV RNA replication. In addition, data obtained in other experimental model systems indicate that HCV has evolved strategies to counteract the antiviral effect of IFN-a. Such mechanisms could contribute to the resistance to IFN-a therapy observed in many patients and may represent a general escape strategy of HCV contributing to viral persistence and pathogenesis. In the following, we will briefly review current concepts of the interaction between cytokines, primarily IFN-a, and HCV.

AB - With an estimated 170 million chronically infected individuals, the hepatitis C virus (HCV) is a major cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma (HCC) worldwide. A protective vaccine does not exist to date and therapeutic options are still limited. At present, inferon-a (IFN-a) in combination with ribavirin is the treatment of choice for chronic hepatitis C. The mechanism of action of IFN-a is only partially understood and may involve both direct antiviral and immunomodulatory effects. Recently, the replicon system has allowed the investigation of the effect of IF-a and other cytokines on HCV RNA replication. In addition, data obtained in other experimental model systems indicate that HCV has evolved strategies to counteract the antiviral effect of IFN-a. Such mechanisms could contribute to the resistance to IFN-a therapy observed in many patients and may represent a general escape strategy of HCV contributing to viral persistence and pathogenesis. In the following, we will briefly review current concepts of the interaction between cytokines, primarily IFN-a, and HCV.

M3 - Conference contribution

SN - 0792387759

SP - 105

EP - 120

BT - Cytokines in liver injury and repair

A2 - Gressner, A. M.

A2 - Heinrich, P. C.

A2 - Matern, S.

PB - Kluwer Academic Publishers

CY - The Netherlands

ER -

Moradpour D, FRESE M, Heim H, Haller O, Bartenschlager R, Blum HE. Cytokines and hepatitis C virus replication. In Gressner AM, Heinrich PC, Matern S, editors, Cytokines in liver injury and repair: proceedings of Falk Symposium No. 125. The Netherlands: Kluwer Academic Publishers. 2002. p. 105-120